This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Medical Technology Companies Poised for Another 'Solid' Quarter, Morgan Stanley Says MT
Morgan Stanley Downgrades Baxter International to Underweight From Equalweight, Cuts Price Target to $30 From $39 MT
Morgan Stanley Downgrades Baxter International to Underweight From Equalweight, Price Target is $30 MT
Citigroup Adjusts Price Target on Baxter International to $37 From $38 MT
Sector Update: Financial Stocks Advance Premarket Monday MT
Sector Update: Financial MT
That's not so bad, is it? Our Logo
Stryker Corporation : Major Player in Medical Devices Our Logo
Health Care Climbs After Baxter Deal - Health Care Roundup DJ
S&P 500, Nasdaq Stretch Record Closing Runs After Jobs Data MT
S&P 500, Nasdaq Stretch Record Closing Runs After Jobs Data MT
Sector Update: Financial Stocks Ease Late Afternoon MT
Sector Update: Financial MT
Carlyle Group Reportedly in Advanced Talks to Buy Baxter's Vantive Business CI
Carlyle Group in Advanced Talks to Acquire Vantive From Baxter MT
Carlyle in talks to buy Baxter's kidney care unit, source says RE
Carlyle in talks to acquire Baxter unit Vantive, WSJ reports RE
Cerus Corporation Appoints Dean Gregory to its Board of Directors CI
Evercore ISI Adjusts Price Target on Baxter International to $45 From $46, Maintains Outperform Rating MT
Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors CI
Transcript : Baxter International Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM
Transcript : Baxter International Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 09:30 AM
Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy CI
Citigroup Adjusts Price Target on Baxter International to $38 From $44, Keeps Neutral Rating MT
Transcript : Baxter International Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Chart Baxter International Inc.
More charts
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
33.97 USD
Average target price
44.75 USD
Spread / Average Target
+31.73%
Consensus
  1. Stock Market
  2. Equities
  3. BAX Stock
  4. News Baxter International Inc.
  5. Citigroup Adjusts Price Target on Baxter International to $37 From $38